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Generation of cell-type-speciﬁc gene
mutations by expressing the sgRNA
of the CRISPR system from the RNA
polymerase II promoters
Dear Editor,
Recently, theCRISPR/Cas9 system is emerging as apowerful
tool for genome editing (Chang et al., 2013; Li et al., 2013; Niu
et al., 2014; Shen et al., 2013; Wan et al., 2015; Wang et al.,
2013) and genetic screening (Konermann et al., 2015), and
holds great promise for biomedical applications in disease
modeling and gene therapy by in vivo genome editing (Mad-
dalo et al., 2014; Xue et al., 2014). However, the applications
ofCRISPR/Cas9 systemstill face some technical hurdles, one
ofwhich is to harness the geneediting in a precisely controlled
manner. Of the two-component CRISPR/Cas9 system for
genome editing, the Cas9 is a ﬁxed genome-cutting compo-
nent expressed from the RNA polymerase II (pol II) promoter
that can drive tissue-speciﬁc gene expression; while the sin-
gle-guide RNA (sgRNA) is a changeable genome-guiding
component expressed from RNA polymerase III (pol III) pro-
moter that usually drives the ubiquitous expression of
“housekeeping” genes in all tissues. Therefore, to express the
sgRNA in a tissue-speciﬁc manner can provide a convenient
approach to tissue-speciﬁc gene mutations. Here, we recon-
structed the sgRNA to enable its expression from the pol II
promoters, and further achieved cell-type speciﬁc gene mu-
tations via the modiﬁed CRISPR/Cas9 system by using cell-
type speciﬁc pol II promoters-driving sgRNA.
To generate pol II promoter-driving sgRNAs, we con-
structed a microRNA-shRNA-embedded sgRNA (miRsh-
sgRNA) cassette that could express the small RNA from pol
II promoter (Wang et al., 2007) into the 3′-untranslational
region (UTR) of the DsRed reporter gene (Figs. 1A and S1,
and Supplementary Materials), as methods by cis-acting ri-
bozymes (Gao & Zhao, 2014; Nissim et al., 2014) and Cas6/
Csy4-based RNA processing (Nissim et al., 2014) have
been reported. Notably, the nonsense shRNAs and a re-
ported efﬁcient sgRNA targeting the mouse p53 gene
(sgp53) (Xue et al., 2014) was adopted in the construct for a
proof-of-concept experiment. The mature sgRNA derived
from the miRsh-sgRNA cassette will have additive 7
nucleotides in the 5′-end (Fig. 1A), so we chose a reported
optimized sgRNA backbone, the sgRNA(F+E), to improve the
mutagenesis efﬁciency (Chen et al., 2013), given that the
sgRNAs with mispairing and addition in the 5′-end are still
functional (Cong et al., 2013).
To test whether functional sgRNA can be efﬁciently
derived from the pol II promoter-driving miRsh-sgRNA cas-
sette, we transfected mouse embryonic ﬁbroblasts (MEFs)
and mouse embryonic stem cells (mESCs) with constitutive
EF1a promoter-driving miRsh-sgp53 expression vector and
Cas9-P2A-EGFP expression vector. GFP and DsRed double
positive cells were sorted by ﬂuorescence-activated cell
sorting (FACS) two days after transfection for further analysis
(Fig. 1B). The T7EN1 cleavage assay of these cells showed
that constitutive EF1a promoter-driving miRsh-sgp53 can
guide Cas9 for producing double strand breaks (DSBs) in
p53 gene in both MEFs and mESCs (Fig. 1C). To conﬁrm the
T7EN1 cleavage results, Sanger sequencing was performed
and the result showed that the efﬁciency of miRsh-sgp53 in
MEFs (Fig. 1D) and mESCs (Fig. 1E) was about 50% (6/12)
and 57.1% (8/14). These results indicated that the functional
sgRNA could be expressed from the pol II promoter-driving
miRsh-sgRNA construct for successful gene mutations.
Further, to examine whether the miRsh-sgRNA cassette
can produce gene mutation in a cell type-speciﬁc manner,
we constructed an expression vector using the embryonic
stem cell-speciﬁc mouse Oct4 gene promoter (mOct4P) to
express the miRsh-sgp53 cassette. Two days after trans-
fection of MEFs and mESCs with this vector and the EF1a
promoter-driving Cas9-P2A-EGFP vector, GFP and DsRed
double-positive mESCs were observed, but only GFP posi-
tive MEFs were observed, indicating the cell-type-speciﬁc
expression of the sgRNA (Fig. 1F). We sorted GFP and
DsRed double positive mESCs and GFP positive MEFs by
FACS for further analysis. T7EN1 cleavage assay and
Sanger sequencing were performed, and p53 gene mutation
was only detected in the mESCs but not in the MEFs
(Fig. 1G). The result of Sanger sequencing showed that the
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p53 mutation efﬁciency in mESCs with ESC-speciﬁc mOc-
t4P-driving miRsh-sgp53 (52.9%, 9/17) was similar to that
with constitutive EF1a promoter-driving sgp53 (Fig. 1H).
These results indicated that the cell type-speciﬁc gene
editing can be achieved by cell type-speciﬁc promoter-driv-
ing expression of miRsh-sgRNA.
Previous studies suggested that CRISPR/Cas9 system
would probably induce off-target mutations because the
binding to genome could tolerate sequence mismatches
distal from the PAM at the 5′ end of sgRNAs. It has been
demonstrated in bacteria and cultured human cells that the
DNA cleavage speciﬁcity of CRISPR/Cas9 system is deter-
mined by the PAM sequence NGG and the 8–12 base ‘‘seed
sequence’’ at the 3′ end of the sgRNA (Cong et al., 2013;
Jinek et al., 2013; Wang et al., 2013). We searched for po-
tential off target sites based on this rule, and found 41
potential off targets of the sgp53 (named p53-off-1 to p53-off-
41) existing in mouse genome (Table S2). The T7EN1 assay
and Sanger sequencing revealed that no potential off target
site we tested (Figs. 1I, 1J and S2) was mutated by miRsh-
sgp53 in all the examined cells.
In conclusion, we designed a new construct for efﬁcient
and visible expression of sgRNAs from the pol II promoters,
which therefore can produce cell-type speciﬁc mutations.
This reconstructed pol II promoter-driving miRsh-sgRNA
backbone will make the CRISPR/Cas9 system-mediated
genome editing be more controllable and safer for future
applications such as in in vivo gene therapy.
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